BioWorld

May 28, 2003

EPIX In $28M Deal To Develop Contrast Agents With Schering

EPIX Medical Inc. is returning to a familiar partner, Schering AG, to develop contrast agents for use in MRI in a deal that could garner up to $28 million in near-term money for EPIX.(BioWorld Today) Read More

Medivir, GSK Agree To EUR86M Deal For Phase I HIV Candidate

Peninsula In-Licenses Late-Stage Antibiotic From Japanese Firm

Vitex Offering Brings In $14.4M For Blood Purifying Technology

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...